Panbela Therapeutics announces poster presentation on ivospemin at AACR

Panbela Therapeutics announces a poster presentation highlighting the results for ivospemin as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research, AACR, which took place April 10, 2024. The work reflects the Company’s on-going collaboration with Johns Hopkins University School of Medicine. “Ivospemin, reduces the viability of human ovarian adenocarcinoma cell lines regardless of their platinum sensitivity and we found that the combination treatment with doxorubicin increases median survival, delays tumor onset, and decreases overall tumor burden compared to either clinical or subclinical doxorubicin dosing schemes.” said Jennifer Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. “The continued work by collaborators at Johns Hopkins University School of Medicine is providing the foundation for the initiation of our ovarian cancer program in this year.”